Structure Therapeutics (NASDAQ:GPCR) Hits New 52-Week Low – Here’s Why

Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) hit a new 52-week low during mid-day trading on Wednesday. The company traded as low as $20.50 and last traded at $20.7660, with a volume of 174,301 shares trading hands. The stock had previously closed at $21.55.

Wall Street Analyst Weigh In

Several analysts recently weighed in on the company. Citizens Jmp restated a “market outperform” rating and issued a $110.00 price objective on shares of Structure Therapeutics in a report on Wednesday, September 9th. HC Wainwright reiterated a “buy” rating on shares of Structure Therapeutics in a report on Wednesday, September 9th. Canaccord Genuity Group set a $111.00 target price on shares of Structure Therapeutics in a research report on Friday, August 7th. Wall Street Zen downgraded shares of Structure Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday, October 3rd. Finally, Citigroup restated a “market outperform” rating on shares of Structure Therapeutics in a report on Friday, August 7th. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $110.91.

Structure Therapeutics Price Performance

The stock has a market capitalization of $1.48 billion, a price-to-earnings ratio of -21.20 and a beta of -1.30. The business has a fifty day moving average of $35.29 and a 200 day moving average of $50.14.

Structure Therapeutics (NASDAQ:GPCR) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.10). On average, equities research analysts expect that Structure Therapeutics Inc. Sponsored ADR will post -1.87 EPS for the current year.

Hedge Funds Weigh In On Structure Therapeutics

Several large investors have recently modified their holdings of GPCR. Assetmark Inc. raised its position in Structure Therapeutics by 21.4% during the first quarter. Assetmark Inc. now owns 2,544 shares of the company’s stock valued at $123,000 after buying an additional 449 shares during the period. Sterling Capital Management LLC bought a new stake in shares of Structure Therapeutics during the 1st quarter worth $28,000. IFP Advisors Inc bought a new position in shares of Structure Therapeutics in the second quarter worth about $46,000. Cetera Investment Advisers boosted its position in shares of Structure Therapeutics by 17.0% in the first quarter. Cetera Investment Advisers now owns 7,720 shares of the company’s stock valued at $372,000 after acquiring an additional 1,124 shares during the period. Finally, China Universal Asset Management Co. Ltd. grew its holdings in Structure Therapeutics by 20.5% during the third quarter. China Universal Asset Management Co. Ltd. now owns 14,957 shares of the company’s stock valued at $489,000 after purchasing an additional 2,548 shares during the period. Institutional investors own 91.78% of the company’s stock.

Structure Therapeutics Company Profile

Structure Therapeutics (NASDAQ: GPCR) is a clinical-stage biopharmaceutical company developing oral small-molecule medicines for chronic metabolic diseases. The company uses structure-based drug discovery and focuses on G protein-coupled receptors (GPCRs), a broad class of drug targets involved in metabolic and cardiovascular processes.

Its lead product candidate is GSBR-1290, an investigational oral GLP-1 receptor agonist being developed for obesity and type 2 diabetes. Structure Therapeutics is also advancing additional discovery and preclinical programs intended to address metabolic and related chronic diseases.